Options for the management of mucosal candidiasis in patients with AIDS and HIV infection (Q40827662)

24 September 2017

1 reference

title

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection (English)

1 reference

24 September 2017

0 references

0 references

1 reference

Vazquez JA

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

76-87

1 reference

Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Acquired immune deficiency syndrome in the United States: the first 1,000 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Current concepts. Treatment of infections associated with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oropharyngeal Candidiasis Treated With a Troche Form of Clotrimazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Drug interactions in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Gastro-oesophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Pharmacology and toxicity of high-dose ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Factors associated with increased frequency of HIV-related oral candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

21 January 2018

Yeasts of human origin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Yeasts from human sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole treatment of candidal infections caused by non-albicans Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Carriage of Oral Candida albicans Associated with a High Number of Circulating Suppressor T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Treatment of oropharyngeal candidiasis in HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Ketoconazole and Candidiasis: A Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

OESOPHAGEAL MONILIASIS IN MALIGNANT NEOPLASTIC DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Asymptomatic esophageal candidiasis in the acquired-immunodeficiency-syndrome-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Oral clotrimazole in the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole vs. Flucytosine in the Treatment of Esophageal Candidiasis in AIDS Patients: A Double-Blind, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Fluconazole-resistant candidosis in an HIV cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.1.76.30509

10.1592/PHCO.19.1.76.30509

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference